Drug Profile
Propranolol opthalmic - Recordati
Alternative Names: REC-0551Latest Information Update: 31 Oct 2021
Price :
$50
*
At a glance
- Originator Meyer Children's Hospital
- Developer Meyer Children's Hospital; Recordati
- Class Antihypertensives; Antimigraines; Class II antiarrhythmics; Ischaemic heart disorder therapies; Naphthalenes; Propanolamines; Small molecules
- Mechanism of Action Beta-adrenergic receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase II/III Retinopathy of prematurity
Most Recent Events
- 05 Oct 2020 Propranolol ophthalmic is still in phase II/II trials for Retinopathy of prematurity in Italy (Ophthalmic) (Recordati company website, October 2020)
- 01 Aug 2018 Meyer Children's Hospital completes the phase II DROP-ROP-0.2% trial in Retinopathy of prematurity in Italy (NCT02504944)
- 07 Mar 2017 Chemical structure information added